Aligos Therapeutics, Inc.
ALGS
$4.08
$0.092.26%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -76.54% | -60.82% | -84.59% | -63.79% | -24.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -76.54% | -60.82% | -84.59% | -63.79% | -24.20% |
| Cost of Revenue | -27.97% | 5.72% | 25.73% | -9.75% | 16.53% |
| Gross Profit | 21.32% | -22.78% | -102.51% | 0.21% | -25.79% |
| SG&A Expenses | -9.41% | -28.20% | -31.04% | -21.63% | -19.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.19% | -4.08% | 5.56% | -13.55% | 6.62% |
| Operating Income | 18.64% | -5.56% | -38.00% | 7.83% | -11.42% |
| Income Before Tax | -194.12% | -6.42% | 129.11% | -52.03% | -27.87% |
| Income Tax Expenses | 190.00% | 213.79% | -75.03% | -38.46% | -161.22% |
| Earnings from Continuing Operations | -194.53% | -6.75% | 126.93% | -51.88% | -27.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -194.53% | -6.75% | 126.93% | -51.88% | -27.44% |
| EBIT | 18.64% | -5.56% | -38.00% | 7.83% | -11.42% |
| EBITDA | 18.32% | -5.96% | -39.61% | 7.25% | -12.27% |
| EPS Basic | -137.66% | 70.39% | 107.44% | 58.27% | 56.92% |
| Normalized Basic EPS | -143.65% | 70.48% | 108.04% | 58.22% | 57.90% |
| EPS Diluted | -137.66% | 70.39% | 106.90% | 58.27% | 56.96% |
| Normalized Diluted EPS | -143.65% | 70.48% | 108.03% | 58.22% | 57.90% |
| Average Basic Shares Outstanding | 23.93% | 260.52% | 262.02% | 263.91% | 195.85% |
| Average Diluted Shares Outstanding | 23.93% | 260.52% | 262.48% | 263.91% | 195.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
